<DOC>
	<DOCNO>NCT02973191</DOCNO>
	<brief_summary>This single-arm , multi-center , open-label , Phase 2 study determine efficacy safety JCAR015 adult subject B-cell ALL . The study divide two sequential part , Part A Part B ; subject screen provide inform consent initiate study procedure Part A study .</brief_summary>
	<brief_title>A Study Determine Safety , Feasibility Efficacy JCAR015 Adult Subjects With B-Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>1 . Age ≥18 year time signing informed consent form 2 . Subject must understand voluntarily sign Informed consent form ( ICF ) prior studyrelated assessments/procedures conduct 3 . Subject willing able adhere study visit schedule protocol requirement 4 . Diagnosis Bcell Acute Lymphoblastic Leukemia ( ALL ) 5 . Evidence CD19 expression via flow cytometry ( peripheral blood bone marrow ) immunohistochemistry ( bone marrow biopsy ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 7 . No contraindication cyclophosphamide . This include subject : hypersensitivity cyclophosphamide , metabolites acute infection bone marrow aplasia bone marrow depression prior treatment urinary tract infection acute urothelial toxicity cytotoxic chemotherapy radiation therapy urinary outflow obstruction obstruction 8 . Adequate organ function , define : a. Serum creatinine ≤ 1.5 × ageadjusted upper limit normal ( ULN ) OR calculate creatinine clearance ( Cockcroft Gault ) &gt; 30 mL/min/1.73 m2 b. Alanine aminotransferase ( ALT ) ≤ 5 × ULN direct bilirubin &lt; 2.0 mg/dL ( &lt; 3.0 mg/dL subject leukemic infiltration liver ) c. Adequate pulmonary function , define ≤ Grade 1 dyspnea oxygen saturation ( SaO2 ) ≥ 92 % room air d. Adequate cardiac function , define leave ventricular ejection fraction ( LVEF ) ≥ 40 % assess echocardiogram ( ECHO ) multiple uptake gated acquisition ( MUGA ) perform within 1 month signing informed consent form 9 . Adequate central peripheral vascular access leukapheresis procedure . For subject require central venous catheter ( CVC ) placement , surgical consultation indicate subject eligibility CVC placement sufficient enrollment . 10 . Subjects must agree donate blood , organ , sperm semen , egg cell usage individual without recipient knowledge exposure genetically modify organ donor inform potential risk associate point receive JCAR015 infusion . 11 . Females childbearing potential ( FCBP1 ) must : . Have two negative pregnancy test verify Investigator ( one negative serum beta human chorionic gonadotropin ( ßhCG ) pregnancy test result within 7 day prior first dose cytoreductive chemotherapy ( Part A screen evaluation ) , one negative serum urine pregnancy test Part B screening evaluation prior first JCAR015 infusion ) . She must agree another pregnancy test 90 day post final JCAR015 dose . This apply even subject practice true abstinence2 heterosexual contact . b . Either commit true abstinence2 heterosexual contact ( must review monthly basis source document ) agree use , able comply , effective contraception without interruption . Contraception method must include 1 highly effective 1 additional effective ( barrier ) method contraception least 28 day prior JCAR015 initial infusion study therapy include dose interruption . Cessation contraception point discuss responsible physician . Note : Highly effective method define result low failure rate ( ie , le 1 % per year ) use consistently correctly . The following example highly effective additional effective method contraception : Intrauterine device ( IUD ) Hormonal ( birth control pill , injection , implant ) Tubal ligation Partner 's vasectomy Male Condom ( additional effective method ) Diaphragm ( additional effective method ) Cervical Cap ( additional effective method ) c. Agree abstain breastfeeding study participation least 90 day last dose JCAR015 . d. Agree use highly effective method contraception entire study period ( Part A 12 month final JCAR015 infusion ) . 12 . Males partner childbearing potential must agree use effective barrier contraceptive method entire study period ( Part A 12 month final JCAR015 infusion ) . Additional Cohort Specific Inclusion Criteria Inclusion Criteria ( Cohorts 14 ) 1 . Relapsed refractory disease , define : 1 . First bone marrow relapse ( prior Complete response ( CR ) duration &lt; 18 month ) subsequent bone marrow relapse Complete response ( CR ) , OR 2 . Any bone marrow relapse allogeneic hematopoietic stem cell transplant ( HSCT ) ; subject must least 2 month HSCT time sign informed consent form immunosuppressant medication least 1 month time sign informed consent form ( exception lowdose steroid ( ≤ 20 mg prednisone equivalent ) , Graft versus host disease ( GVHD ) , OR 3 . Refractory Acute Lymphoblastic Leukemia ( ALL ) , define achieve Complete response ( CR ) Complete response incomplete peripheral blood count recovery ( CRi ) two attempt remission induction use standard chemotherapy regimen , OR 4 . Philadelphia chromosome positive ( Ph+ ) Bcell ALL subject intolerant , ineligible , Tyrosine kinase inhibitor ( TKI ) therapy , progress least one line TKI therapy . 2 . Bone marrow morphological evidence disease ( ≥ 5 % blast morphology ) . Inclusion Criteria [ Ph ( + ) ( Cohort 3 ) ] All subject must meet Inclusion criterion describe Cohort 1 . Inclusion Criteria ( Cohort 4 ) 1 . Eligible Cohorts 13 investigator decide administer blinatumomab standard ALL therapy rather alternative list leukapheresis prior part B therapy Inclusion Criteria ( MRD Positive+ [ Cohort 5 ] ) Inclusion criterion Cohorts 1 2 , exception : 1 . Bone marrow without morphological evidence disease characterize ≤ 5 % blast morphology , MRD detect flow cytometry , qPCR frequency ≥ 1 x 104 follow standard care induction consolidation therapy CR1 subsequent CR For subject MRD follow flow cytometry , nucleic acid sample leukemia blast sufficient quality must available generate realtime quantitative PCR ( RQPCR ) primer . 4.2.2 . Inclusion Criteria ( Part B ) 1 . Completion Part A successful generation JCAR015 cell product 2 . Results bone marrow examination follow Part A : 1 . Group 1 : Morphological evidence disease ( ≥ 5 % blast morphology ) 2 . Group 2 : Morphologic complete remission ( bone marrow &lt; 5 % blast ) without blood count recovery ( CR CRi ) hypoplastic , aplastic , `` recovery '' marrow Day 42 Part A 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 4 . Adequate organ function , define : 1 . Serum creatinine ≤ 1.5 × ageadjusted ULN OR calculate creatinine clearance 2 . ( Cockcroft Gault ) &gt; 30 mL/min/1.73 m2 3 . ALT ≤ 5 × ULN ( ≤ 8 × ULN subject leukemic infiltration liver ) direct bilirubin &lt; 2.0 mg/dL ( &lt; 3.0 mg/dL subject leukemic infiltration liver ) 4 . Adequate pulmonary function , define ≤ Grade 1 dyspnea SaO2 ≥ 92 % room air 5 . Females childbearing potential male partner childbearing potential follow inclusion criterion Part A . 1 . Isolated extramedullary disease relapse 2 . Concomitant genetic syndrome Fanconi anemia , Kostmann syndrome , Shwachman syndrome , know bone marrow failure syndrome 3 . Burkitt 's lymphoma/leukemia chronic myelogenous leukemia ( CML ) lymphoid blast crisis ( p210 BCRABL+ ) 4 . Prior malignancy , unless treat curative intent evidence active disease present &gt; 5 year sign informed consent form , follow exception : . Subjects Stage I breast cancer completely successfully treat , require therapy antihormonal therapy b . Subjects T1N0M0 T2N0M0 colorectal cancer completely successfully resect diseasefree &gt; 2 year prior screen c. Subjects indolent prostate cancer , define clinical stage T1 T2a , Gleason score ≤ 6 , prostatespecific antigen ( PSA ) &lt; 10 ng/mL , require therapy anti hormonal therapy d. Subjects history basal cell squamous cell carcinoma skin , carcinoma situ cervix , fully resect , evidence active disease 5 . Treatment prior gene therapy product 6 . Active hepatitis B , active hepatitis C , human immunodeficiency virus ( HIV ) infection time sign informed consent form 7 . Systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) time sign informed consent form 8 . Presence Grade IIIV ( Glucksberg ) BD ( IBMTR ) acute extensive chronic GVHD time sign informed consent form 9 . Active C S involvement malignancy , define CNS3 per NCCN guideline . Subjects history Central nervous system ( CNS ) disease effectively treat ( defined one document negative CSF evaluation within 1 month prior sign inform consent form ) eligible 10 . History one follow cardiovascular condition within past 6 month sign informed consent form : Class III IV heart failure define New York Heart Association ( NYHA ) , cardiac angioplasty stenting , myocardial infarction , unstable angina , clinically significant cardiac disease 11 . History presence clinically relevant CNS pathology epilepsy , generalized seizure disorder , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis 12 . Participation investigational research study use investigational agent within 30 day sign informed consent form , exception investigational antiinfective agent ( eg , antibacterial , antifungal , antiviral ) 13 . History treatment murinederived biological product ( unless subject show negative human antimouse antibody [ HAMA ] prior screen ) . Prior use blinatumomab permit ( provided evidence CD19 expression per Part A Inclusion Criterion # 4 ) . Chimeric biological product ( eg , rituximab ) consider murine purpose protocol . 14 . Pregnant nursing ( lactate ) woman 15 . Use prohibit medication : a. Steroids : Therapeutic dos corticosteroid ( define &gt; 20 mg/day prednisone equivalent ) prohibit within 7 day prior leukapheresis . Physiologic replacement dose steroid ( ≤ 12 mg/m2/day hydrocortisone equivalent [ ≤ 3 mg/m2/day prednisone ≤ 0.45 mg/m2/day dexamethasone ] ) allow . Topical steroid intrathecal steroid CNS relapse prophylaxis permit . b. Allogeneic cellular therapy : Donor lymphocyte infusion ( DLI ) prohibit within 4 week prior leukapheresis c. GVHD therapy : Any drug use GVHD within 4 week prior leukapheresis , eg , calcineurin inhibitor , methotrexate chemotherapeutics , mycophenolate mofetil , rapamycin , thalidomide , immunosuppressive antibody ( antiCD20 [ rituximab ] , antiTNFα , antiIL6 , antiIL6R ) d. Chemotherapies : Salvage chemotherapy ( eg , cytosine arabinoside &gt; 100 mg/m2/day , anthracyclines , cyclophosphamide ) must stop least 1 week prior leukapheresis 16 . Treatment alemtuzumab within 6 month prior leukapheresis , treatment clofarabine cladribine within 3 month prior leukapheresis 17 . Uncontrolled medical , psychological , familial , sociological , geographical condition permit compliance protocol , judge Investigator ; subject unwillingness inability follow procedure require protocol 4.3.2 . Exclusion Criteria ( Part B ) Subjects must meet following criterion prior Part B consider eligible : 1 . Systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) 2 . Active CNS involvement malignancy , define CNS3 per NCCN guideline . Subjects history CNS disease effectively treat ( defined one document negative CSF evaluation within 1 month prior sign inform consent form ) eligible 3 . Presence clinically relevant CNS pathology epilepsy , generalized seizure disorder , paresis , aphasia , stroke , severe brain injury , dementia , Parkinson 's disease , cerebellar disease , organic brain syndrome , psychosis 4 . Presence Grade IIIV ( Glucksberg ) BD ( IBMTR ) acute extensive chronic GVHD 5 . Use prohibit medication 6 . Female subject positive serum urine pregnancy test , pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>B-Cell Acute Lymphoblastic Leukemia</keyword>
	<keyword>JCAR015</keyword>
</DOC>